Before diving into stem therapy, it helps to revisit what long COVID is, and why immune dysregulation is one of its central features.

Key features of long COVID

Long COVID, also known as post-COVID-19 condition or post-acute sequelae of SARS-CoV-2, refers to a complex cluster of symptoms that persist for weeks or months after the initial infection has resolved. These symptoms vary widely and often occur even in individuals who had only mild or asymptomatic initial cases.

Commonly reported symptoms include:

Persistent fatigue or exhaustion
Shortness of breath or reduced exercise tolerance
Brain fog or cognitive slowing
Chest discomfort or heart palpitations
Muscle and joint aches
Sleep disturbances
Gastrointestinal issues
Autonomic dysfunction, such as dizziness upon standing

While the range of symptoms is broad, what connects many long COVID cases is a form of ongoing immune dysregulation. For some patients, it's as if the immune system was never fully reset after the infection.

Immune dysregulation in long COVID — what the evidence suggests

The immune system's involvement in long COVID has been one of the most researched and debated areas in the post-pandemic medical landscape. Studies suggest that in many long COVID cases, the immune system either remains in a hyperactive state or develops an inappropriate response to previously harmless stimuli.

Some notable findings include:

Elevated inflammatory markers, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), persisting long after infection.
Altered immune cell profiles, including exhausted T cells and shifts in regulatory T cell populations.
Evidence of autoantibody formation, suggesting autoimmune-like activity.
Potential reservoirs of viral RNA or proteins lingering in tissues, possibly driving chronic immune activation.
Ongoing microvascular inflammation or endothelial damage contributing to symptoms like brain fog and fatigue.

From the perspective of an internal medicine specialist, especially one familiar with long-term disease management like Dr. Yoo Du-yeol at Sangdo Woori Internal Medicine Clinic, this type of immune imbalance closely mirrors what we see in chronic inflammatory or autoimmune conditions. In these cases, the goal is not to boost the immune system but to guide it back to balance.

What Is “Stem Therapy” in This Context?

Stem cell therapy, in the context of long COVID, usually refers to the use of mesenchymal stem or stromal cells (MSCs). These are not embryonic stem cells but adult multipotent cells found in bone marrow, adipose tissue, and umbilical cord tissue.

What makes MSCs potentially useful in immune-related conditions is their dual role:

Immunomodulation: MSCs can downregulate inflammatory responses and shift immune activity toward a more regulatory, less aggressive state. This may help reduce chronic inflammation.
Tissue repair and regeneration: Through paracrine signaling, MSCs release growth factors and cytokines that aid in tissue repair, angiogenesis, and fibrosis reduction.

MSCs do not need to transform into other cell types to be therapeutic. Their benefit lies in their ability to act as cellular "conductors," orchestrating a more appropriate immune and repair response.

Another area of interest is MSC-derived exosomes—tiny vesicles that carry proteins, microRNAs, and other signaling molecules. These can potentially offer many of the benefits of MSCs without the complexity of transplanting live cells.

What Does the Evidence So Far Suggest?

Stem therapy in long COVID is still an evolving field, but emerging research has offered some promising insights.

Early studies and observations

Initial studies, particularly those exploring MSCs in severe or hospitalized COVID-19 cases, found that:

MSC therapy was generally well-tolerated with no major adverse effects.
Treated patients showed reduced inflammation markers.
Follow-up data suggested improved lung function and quality of life.

Transitioning to long COVID specifically, small studies and observational reports have shown:

Adipose-derived autologous MSCs helped reduce fatigue, brain fog, and breathlessness in patients when given over multiple sessions.
Umbilical cord-derived MSCs showed potential in restoring immunoglobulin levels and reducing interstitial lung damage.
Exosome therapy is being explored for its ability to cross the blood-brain barrier and target neurological symptoms like brain fog.

A noteworthy long-term study followed patients who had received MSCs during acute COVID and found that many continued to report improvements in energy, lung function, and sleep patterns over 12 to 24 months.

While these findings are encouraging, they are not yet definitive. Most studies are small, non-randomized, and lack placebo-controlled arms. As a result, they are hypothesis-generating rather than practice-changing.

What Are the Challenges, Risks, and Unknowns?

From a clinical perspective, particularly in a patient-centered setting like Sangdo Woori Internal Medicine Clinic, it’s crucial to balance optimism with caution.

Major unknowns

Patient selection: Long COVID is not a single disease but a syndrome with multiple overlapping phenotypes. Which patients benefit from stem therapy? Those with lung damage? Autoimmune signatures? Autonomic dysfunction?
Timing and dosing: The optimal number of doses, timing of infusions, and delivery route (intravenous vs. local injection) remain unclear.
Durability: Are the effects of stem therapy long-lasting or temporary? Will repeated treatments be necessary?
Interaction with other treatments: How does stem therapy interact with standard treatments like corticosteroids, antihistamines, or rehabilitation?

Safety and regulatory concerns

While MSC therapy appears safe in early trials, the long-term risks—including the possibility of unwanted immune modulation or fibrosis—are not fully known.
Unregulated clinics have started offering stem cell treatments for long COVID outside of clinical trials. These pose significant safety, ethical, and financial risks.
South Korea has robust regulatory systems, but patients must be vigilant and seek only reputable providers.

At Sangdo Woori Internal Medicine Clinic, we emphasize that any patient considering stem therapy for long COVID should do so under the supervision of a licensed physician and ideally within the context of a clinical study.

How Could Stem Therapy Fit Into a Broader “Immune Support / Recovery” Strategy?

Rather than viewing stem therapy as a standalone solution, it may be more realistic and beneficial to integrate it into a multi-pronged recovery strategy.

Phenotype-first approach

Long COVID manifests differently in each patient. The key to recovery is personalized medicine—something we prioritize at Sangdo Woori. Identifying whether a patient is dealing with lung fibrosis, vascular inflammation, autonomic dysfunction, or neurocognitive impairment is essential before considering advanced therapies.

Complementary therapies

Stem therapy, if used, should complement rather than replace established interventions:

Rehabilitation: Graded exercise therapy, pulmonary rehab, and cognitive retraining can help restore function.
Metabolic and endocrine evaluation: Thyroid dysfunction, diabetes, and adrenal fatigue are commonly unmasked post-COVID. Dr. Yoo Du-yeol emphasizes routine endocrine workups for patients with lingering fatigue or weight changes.
Nutritional support: Correcting micronutrient deficiencies and ensuring optimal gut health can support immune normalization.
Psychological care: The mental burden of long COVID is profound. Integrated care should include counseling, sleep therapy, and, when needed, psychiatric support.

Close monitoring

Patients undergoing or considering stem therapy should be closely followed with serial lab testing, symptom tracking, imaging, and functional assessments. Objective improvement must guide decisions about continuation or modification.

Bottom Line: Could Stem Therapy Help Immune Support in Long COVID?

Yes—with careful selection, close monitoring, and appropriate expectations, stem therapy could represent a valuable tool in long COVID recovery. But it is not a universal solution.

From the standpoint of Sangdo Woori Internal Medicine Clinic and Dr. Yoo Du-yeol, we believe stem therapy holds promise, particularly for patients with documented immune dysregulation or organ-specific injury who have not responded to standard care.

But we also emphasize the foundational principles of good medicine:

Understand the patient’s unique story.
Identify treatable patterns through testing and conversation.
Guide the immune system back to balance, rather than just boosting it.
Use advanced therapies as part of a coordinated, evidence-informed plan.

If you’ve experienced long COVID symptoms that persist beyond the expected recovery window, especially fatigue, breathlessness, or unexplained inflammatory markers, consider consulting a comprehensive internal medicine clinic like Sangdo Woori. Our focus on whole-person care, combined with expertise in endocrinology and chronic disease, allows us to tailor treatment plans that truly support long-term recovery.

Stem therapy might be part of that plan—but only when it makes sense for you.